Latest Tyrosine kinases Stories
-Significant synergy resulted with combination treatment of pacritinib and cytarabine or a MEK inhibitor- SEATTLE, Dec. 9, 2014 /PRNewswire/ -- CTI BioPharma Corp.
-Profile Supports Potential Role in Modulating Tumor Microenvironment in Blood-Related Cancers, Including AML, MDS, CMML and CLL- SEATTLE, Dec.
SEATTLE, Dec. 1, 2014 /PRNewswire/ -- CTI BioPharma Corp.
LONDON, Oct. 14, 2014 /PRNewswire/ -- REPORT HIGHLIGHTSThe global market for signal transduction therapies/inhibitors (JAK and PI3K) reached $173.5 million in 2012.
SAN DIEGO, Aug.
Research in mice and human cell lines has identified an experimental compound dubbed TTT-3002 as potentially one of the most potent drugs available to block genetic mutations in cancer cells blamed for some forms of treatment-resistant leukemia.
- To fire mitraille at.